Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates

作者: Martin L. Ashdown , Andrew P. Robinson , Steven L. Yatomi-Clarke , M. Luisa Ashdown , Andrew Allison

DOI: 10.12688/F1000RESEARCH.6760.1

关键词:

摘要: Complete response (CR) rates reported for cytotoxic chemotherapy late-stage cancer patients are generally low, with few exceptions, regardless of the solid type or drug regimen. We investigated CR in literature clinical trials using alone, across a wide range tumour types and chemotherapeutic regimens, to determine an overall rate cancers. A total 141 reports were located PubMed database. meta-analysis was performed from 68 (total 2732 patients) standard agents cancers—a binomial model random effects adopted. Mean compared different types, mechanisms action, logistic regression. Our results showed that treatment low at 7.4%, regimen used. found no evidence differed between but amongst small differences evident, although none exceeded mean 11%. This remarkable concordance therapy remains currently unexplained, motivates further investigation.

参考文章(106)
William K. Oh, Susan Halabi, W. Kevin Kelly, Cary Werner, Paul A. Godley, Nicholas J. Vogelzang, Eric J. Small, , A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer. ,vol. 98, pp. 2592- 2598 ,(2003) , 10.1002/CNCR.11829
Hsing-Pang Lu, CC Chao, None, Cancer cells acquire resistance to anticancer drugs: An update Biomedical journal. ,vol. 35, pp. 464- 472 ,(2012) , 10.4103/2319-4170.104411
Brigette B. Y. Ma, Ian F. Tannock, Gregory R. Pond, Matthew R. Edmonds, Lillian L. Siu, Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma Cancer. ,vol. 95, pp. 2516- 2523 ,(2002) , 10.1002/CNCR.10995
D Santini, F Graziano, V Catalano, M Di Seri, E Testa, AM Baldelli, P Giordani, A La Cesa, B Spalletta, B Vincenzi, A Russo, M Caraglia, V Virzi, S Cascinu, G Tonini, Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial BMC Cancer. ,vol. 6, pp. 125- 125 ,(2006) , 10.1186/1471-2407-6-125
Dae Ho Lee, So Young Ju, Hyae Young Kim, Ji-Youn Han, Eun Hee Shin, Jae Jin Lee, Eun-A Kim, Jin Soo Lee, A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer. Clinical Cancer Research. ,vol. 9, pp. 5909- 5914 ,(2003)
Donald Kaufman, Derek Raghavan, Michael Carducci, Ellis Glenn Levine, Barbara Murphy, Joseph Aisner, Timothy Kuzel, Steven Nicol, William Oh, Walter Stadler, Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer Journal of Clinical Oncology. ,vol. 18, pp. 1921- 1927 ,(2000) , 10.1200/JCO.2000.18.9.1921
Mark Baekelandt, Gustav Lehne, Claes G. Tropé, István Szántó, Per Pfeiffer, Bengt Gustavssson, Gunnar B. Kristensen, Phase I/II Trial of the Multidrug-Resistance Modulator Valspodar Combined With Cisplatin and Doxorubicin in Refractory Ovarian Cancer Journal of Clinical Oncology. ,vol. 19, pp. 2983- 2993 ,(2001) , 10.1200/JCO.2001.19.12.2983
Colin B. Begg, Madhuchhanda Mazumdar, Operating characteristics of a rank correlation test for publication bias. Biometrics. ,vol. 50, pp. 1088- 1101 ,(1994) , 10.2307/2533446
Emilio Bajetta, Maria Di Bartolomeo, Luigi Mariani, Antonio Cassata, Salvatore Artale, Sergio Frustaci, Graziella Pinotti, Andrea Bonetti, Ignazio Carreca, Guido Biasco, Luigi Bonaglia, Giovanni Marini, Antonio Iannelli, Diego Cortinovis, Ermina Ferrario, Elena Beretta, Antonio Lambiase, Roberto Buzzoni, Italian Trials in Medical Oncology (ITMO) Group, Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma Cancer. ,vol. 100, pp. 279- 287 ,(2004) , 10.1002/CNCR.11910